Under the agreement, BPR will distribute and provide support for Medclair’s MDU device, which, when combined with BPR’s Ultraflow demand valve and a gas scavenging system, is said to capture nitrous oxide and convert 99% of the gas to harmless nitrogen and oxygen.
BPR Medical emphasises that nitrous oxide is used by 80 per cent of women in labour in the UK, and also widely in other hospital departments – from endoscopy to dentistry. The gas is among the most environmentally harmful anaesthetic gases, with a global warming potential 298 times that of carbon dioxide (CO2).
CEO of Medclair, Jonas Lundh, said: “Capturing and converting nitrous oxide emissions could reduce NHS anaesthetic gas emissions by a third if the technology was implemented across all UK hospital Trusts. The agreement with BPR – which has a strong presence and reputation in the market with its inhaled analgesia products – is a major step forward in our goal of supporting the NHS with its environmental targets.”
Richard Radford, MD at BPR Medical, explained: “The NHS has one of the world’s most developed nitrous oxide programmes, delivering safe, efficient pain relief to hundreds of patients every day. However, the gas has a significant impact on the environment, and can also affect working conditions for staff. There is now a solution though, successfully deployed in Scandinavia for almost two decades, and already being used in hospitals across the UK. Our agreement with Medclair means we can continue to help more Trusts play their part in achieving ‘Net Zero’ goals and meet audit standards.”
Head of Sales & Marketing at BPR Medical, Safoura Sardari, added: “Early adopters are already embracing this technology, including Trusts in Scotland, the north-east of England, London, Wales, and the south-west. We are now expanding our business development team to meet the increasing demand from the NHS and private healthcare settings UK-wide.”